Message Font: Serif | Sans-Serif
No. of Recommendations: 3
I typically don't post much on pharma as I find the upside limiting, but this dataset was, on first glance, spectacular and potentially life changing for large numbers of patients so I had to post.

In an update on their drug Kisqali combined with endocrine therapy, researchers highlighted a 70.2% survival rate among pre-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer 42 months after treatment began. That’s significantly better — with a 27% drop in the risk of death — than the former standard of care, where 46% of patients in the Monaleesa-7 control arm were still alive.

Hats off to Novartis, they also ran solid trials with patient oriented outcomes: progression free survival! These are the types of trials that we should be looking for. Positive data from large, placebo controlled trials with survival as main outcome.

Great news for patients.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.